Galmed Pharmaceuticals Has Received A Notice Of Allowance For A U.S. Patent Titled "TREATMENT FOR FIBROSIS AND INHIBITION OF FIBROSIS"
Galmed Pharmaceuticals Has Received A Notice Of Allowance For A U.S. Patent Titled "TREATMENT FOR FIBROSIS AND INHIBITION OF FIBROSIS"
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.